Colombia to India Pharmaceutical Import

The pharmaceutical trade corridor between Colombia and India has experienced modest activity from 2022 to 2026. During this period, India imported pharmaceutical formulations from Colombia totaling $2,000 USD across 26 shipments. The average shipment value was approximately $64 USD, indicating a niche but consistent trade relationship. The primary product imported was Budesonide, accounting for 66.8% of the total import value. Other notable imports included Serum (13.4%), Erlotinib (9.1%), and Ibuprofen (6.5%). This suggests a focus on respiratory and oncology treatments, along with pain management.

Colombia's contribution to India's pharmaceutical imports remains relatively small, with a total import value of $2,000 USD over the past four years. This positions Colombia as a minor supplier in India's diverse pharmaceutical import portfolio. The imports predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The therapeutic areas covered by these imports align with India's healthcare needs, particularly in respiratory, oncology, and pain management sectors.

Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Colombia. Trade agreements or regulatory harmonization efforts during this period have not notably impacted this bilateral trade corridor. The steady nature of this trade suggests a stable, albeit limited, engagement between the two nations in the pharmaceutical sector.

For Colombian pharmaceutical companies aiming to export to India, obtaining registration with the CDSCO is mandatory. The process involves several key steps:

1. Appointment of Authorized Indian Representative (AIR): Colombian manufacturers must appoint an AIR in India, as foreign entities cannot apply directly. The AIR is responsible for all regulatory submissions to the CDSCO.

2. Submission of Application: The AIR submits an online application through the CDSCO's SUGAM portal, providing details about the manufacturer, products, and compliance with Indian regulations.

3. Documentary Requirements: Essential documents include a Power of Attorney from the manufacturer, Site Master File, Plant Master File, Free Sale Certificate, and a list of products intended for export.

4. Review and Approval: The CDSCO reviews the application and may conduct inspections. Upon satisfactory evaluation, a registration certificate is issued, typically valid for three years.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as per WHO guidelines. Manufacturers must provide a Site Master File detailing their compliance with GMP, quality assurance systems, and manufacturing processes. The CDSCO may conduct inspections to verify adherence to these standards. Additionally, a Free Sale Certificate from the country of origin is necessary to demonstrate that the products are freely sold and distributed in the exporting country.

To import pharmaceutical products into India, Colombian companies must ensure the following documentation is in place:

1. Import License (Form 10): Required for the importation of drugs into India.

2. Registration Certificate: Issued by the CDSCO, confirming that the product is registered for sale in India.

3. No Objection Certificate (NOC): A certificate from the manufacturer stating that the product is not under any patent or exclusive marketing rights in India.

4. Test License: If the product is intended for testing or clinical trials, a test license is required.

5. Customs Procedures: Compliance with Indian customs regulations, including proper labeling, packaging, and documentation, is essential for smooth clearance.

The pharmaceutical imports from Colombia to India are concentrated in specific therapeutic areas:

• Respiratory Treatments: Budesonide, a corticosteroid used in asthma management, is the leading import, indicating a demand for respiratory medications.

• Oncology Treatments: Erlotinib, an anti-cancer agent, reflects India's ongoing need for cancer therapies.

• Pain Management: Ibuprofen, a non-steroidal anti-inflammatory drug, addresses the widespread requirement for pain relief medications.

These categories align with India's healthcare priorities, suggesting that Colombian exports cater to critical medical needs within the country.

Colombian pharmaceutical exports to India include innovator drugs and novel formulations not widely manufactured domestically. Products like Erlotinib and Budesonide represent specialized treatments that may not have extensive local production, highlighting Colombia's role in supplying unique pharmaceutical solutions to the Indian market.

India's imports from Colombia are driven by several factors:

• Patent Protection: Certain drugs, such as Erlotinib, are under patent protection, necessitating imports from the patent-holding country.

• Technology Gaps: Colombia's advanced pharmaceutical manufacturing capabilities fill specific gaps in India's domestic production.

• Quality Requirements: Colombian products meet international quality standards, appealing to Indian buyers seeking high-quality pharmaceuticals.

• Disease Burden: The prevalence of conditions like asthma and cancer in India creates a sustained demand for specialized treatments available through imports.

India's import tariff structure for pharmaceutical formulations includes:

• Most Favored Nation (MFN) Tariff Rates: Standard rates applied to imports from all WTO member countries.

• Basic Customs Duty: A percentage of the product's value, subject to change based on government policies.

• Integrated Goods and Services Tax (IGST): Applied on imported goods, including pharmaceuticals.

• Health Cess: An additional levy on certain imported health-related products.

These duties and taxes are subject to periodic revisions by the Indian government.

As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Colombia that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations but does not include specific provisions for pharmaceutical products between them.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under certain conditions, potentially affecting the pricing and availability of imported drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including those imported, to ensure affordability. These policies can influence the dynamics of pharmaceutical imports from Colombia to India.

Pharmaceutical shipments from Colombia to India typically utilize major sea routes, with transit times ranging from 30 to 45 days, depending on the specific ports of departure and arrival. Air freight options are also available, offering faster delivery times but at higher costs. The reliability of these routes is generally high, with established shipping lines and logistics providers facilitating the movement of goods.

In Colombia, major export ports handling pharmaceutical shipments include Cartagena and Buenaventura. In India, key import ports for pharmaceuticals are Mumbai, Chennai, and Kolkata. These ports are equipped with facilities to handle pharmaceutical products, ensuring compliance with international shipping standards and regulations.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation, inspection of goods, and payment of applicable duties and taxes. The CDSCO conducts quality testing to ensure compliance with Indian standards. For temperature-sensitive products, adherence to cold chain logistics is mandatory, with compliance to Good Distribution Practices (GDP) ensuring product integrity throughout the supply chain.

Despite being a major pharmaceutical manufacturer, India imports specific drugs from Colombia due to factors such as patent protection, technology gaps, and the need for high-quality products. The demand for specialized treatments not widely produced domestically creates a niche market for Colombian pharmaceutical exports.

Colombian pharmaceutical companies exporting to India include GLENMARK PHARMACEUTICALS COLOMBIA SAS, CL